Ubs Group Ag Aveo Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$8.48 - $14.97 $1.63 Million - $2.87 Million	191,896 Added 11566.97%	193,555 $2.89 Million
Q3 2022 Nov 10, 2022	SELL	$6.61 - $8.72 $3,318 - $4,377	-502 Reduced 23.23%	1,659 $13,000
Q2 2022 Aug 10, 2022	SELL	$3.51 - $6.67 $11,558 - $21,964	-3,293 Reduced 60.38%	2,161 $14,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $3,861 - $7,368	-1,226 Reduced 18.35%	5,454 $31,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $30,391 - $47,952	6,480 Added 3240.0%	6,680 $31,000
Q2 2021 Aug 13, 2021	SELL	$6.21 - $7.45 $5,688 - $6,824	-916 Reduced 82.08%	200 $1,000
Q1 2021 May 12, 2021	SELL	$5.97 - $15.28 $33,366 - $85,399	-5,589 Reduced 83.36%	1,116 $9,000
Q4 2020 Feb 11, 2021	BUY	$5.08 - $6.68 $30,419 - $39,999	5,988 Added 835.15%	6,705 $39,000
Q3 2020 Nov 12, 2020	SELL	$4.16 - $6.26 $17,987 - $27,068	-4,324 Reduced 85.78%	717 $4,000
Q2 2020 Jul 31, 2020	BUY	$3.47 - $9.99 $15,719 - $45,254	4,530 Added 886.5%	5,041 $26,000
Q1 2020 May 01, 2020	BUY	$2.6 - $6.9 $1,328 - $3,525	511 New	511 $2,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.